Results 91 to 100 of about 218,916 (388)
EBV and Apoptosis: The Viral Master Regulator of Cell Fate?
Viruses, 2017 Epstein–Barr virus (EBV) was first discovered in cells from a patient with Burkitt lymphoma (BL), and is now known to be a contributory factor in 1–2% of all cancers, for which there are as yet, no EBV-targeted therapies available.
Leah Fitzsimmons, G. Kelly
semanticscholar +1 more source
Viruses, 2023 Epstein-Barr virus (EBV) causes lifelong infection in over 90% of the world’s population. EBV infection leads to several types of B cell and epithelial cancers due to the viral reprogramming of host-cell growth and gene expression. EBV is associated with 10% of stomach/gastric adenocarcinomas (EBVaGCs), which have distinct molecular, pathological, and ...
Mikhail Y. Salnikov +5 more
openaire +3 more sources
A Prion‐Like Domain in EBV EBNA1 Promotes Phase Separation and Enables SRRM1 Splicing
Advanced Science, EarlyView.This study discoveries that EBV EBNA1 behaves as a prion‐like protein, verified using cell‐based assays and the Saccharomyces cerevisiae Sup35p prion identification system. The prion‐like domain of EBNA1 drives liquid–liquid phase separation. EBNA1 interacts with the splicing factor SRSF1 to regulate the expression of the SRRM1 splicing isoforms ...
Xiaoyue Zhang +17 more
wiley +1 more source
International Journal of General Medicine, 2022 Jingjing Wang,1 Yaping Li,2 Xiaozhen Geng,2 Xin Zhang,2 Yanfeng Xiao,1 Wenjun Wang2 1Department of Pediatrics, Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, People’s Republic of China; 2Department of Infectious Diseases, Second
Wang J +5 more
doaj
American Journal of Transplantation, 2016 The molecular pathogenesis of posttransplant diffuse large B cell lymphoma (PT‐DLBCL) is largely unknown. We have recently shown that Epstein‐Barr virus–positive (EBV+) and –negative (EBV−) PT‐DLBCL have distinct gene expression profiles, and the ...
J. F. Ferreiro +8 more
semanticscholar +1 more source
Curcuminoids as EBV Lytic Activators for Adjuvant Treatment in EBV-Positive Carcinomas [PDF]
Cancers, 2018 Epstein-Barr virus (EBV) persists in nasopharyngeal (NPC) and gastric carcinomas (EBVaGC) in a tightly latent form. Cytolytic virus activation (CLVA) therapy employs gemcitabine and valproic acid (GCb+VPA) to reactivate latent EBV into the lytic phase and antiviral valganciclovir to enhance cell death and prevent virus production.
Octavia Ramayanti +5 more
openaire +4 more sources
Advanced Science, EarlyView.This study identifies a novel mechanism of nasopharyngeal carcinoma (NPC) cisplatin chemoresistance that DDAH1 expression is associated with cisplatin resistance in NPC cells primarily through the enhancement of the phosphoinositide Janus kinase 2 (JAK2)‐signal transducer and activator of transcription 3 (STAT3) pathway.
Jin‐Hao Yang +10 more
wiley +1 more source
lHuman cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis [PDF]
, 2005 Effector-memory T cells expressing Fas (Apo-1/CD95) are switched to an apoptotic program by cross-linking with Fas-ligand (FasL). Consequently, tumors that express FasL can induce apoptosis of infiltrating Fas-positive T lymphocytes and subdue any ...
Biagi, E +8 more
core
American Journal of Transplantation, 2015 We examined the associations of Epstein–Barr virus (EBV) status with characteristics and outcomes of posttransplantation lymphoproliferative disorder (PTLD) by studying 176 adult solid organ transplant recipients diagnosed with PTLD between 1990 and 2013
M. Luskin +11 more
semanticscholar +1 more source
GMS Current Posters in Otorhinolaryngology - Head and Neck Surgery, 2017 88.
Wittig, L, Stuck, B, Lang, S, Dominas, N
openaire +1 more source